The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis
Background and Objective: Over the past few years, mirabegron has been increasingly used as a therapeutic option for neurogenic lower urinary tract dysfunction. Here, we carried out a meta-analysis to investigate the efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tra...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/34666b1123054fabab7c18f7846f139b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:34666b1123054fabab7c18f7846f139b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:34666b1123054fabab7c18f7846f139b2021-11-18T06:16:21ZThe Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis1663-981210.3389/fphar.2021.756582https://doaj.org/article/34666b1123054fabab7c18f7846f139b2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.756582/fullhttps://doaj.org/toc/1663-9812Background and Objective: Over the past few years, mirabegron has been increasingly used as a therapeutic option for neurogenic lower urinary tract dysfunction. Here, we carried out a meta-analysis to investigate the efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction.Methods: We used a range of databases to retrieve randomized controlled trials (RCTs) relating to mirabegron in patients with neurogenic lower urinary tract dysfunction: PubMed, Embase, and Cochrane Library; our strategy conformed to the PICOS (populations, interventions, comparators, outcomes, and study designs) strategy.Results: Our analyses involved four RCTs involving 245 patients. We found that mirabegron treatment resulted in a significant improvement in bladder compliance [mean difference (MD) = 19.53, 95% confidence interval (CI): 14.19 to 24.87, P < 0.00001], urinary incontinence episodes (MD = −0.78, 95% CI: −0.89 to −0.67, P < 0.00001) and Incontinence Quality of Life (I-QOL) (MD = 8.02, 95% CI: 3.20 to 12.84, P = 0.001). Significant differences were detected in terms of Patient Perception of Bladder Condition (PPBC) (MD = −0.54, 95% CI: −1.46 to 0.39, P = 0.26) and urinary urgency episodes (MD = −0.72, 95% CI: −3.1 to 1.66, P = 0.55). With regard to safety, there were no significant differences between mirabegron and control groups in terms of the incidence of drug-related adverse events [odds ratio (OR): 0.83, 95% CI: 0.43 to 1.59, P = 0.57], arrhythmias (OR: 1.27, 95% CI: 0.37 to 4.38, P = 0.70), hypertension (OR: 0.70, 95% CI: 0.13 to 3.82, P = 0.68), or post-voiding residual volume (MD: 1.62, 95% CI: −9.00 to 12.24, P = 0.77).Conclusion: Mirabegron is an efficacious and safe treatment for patients with neurogenic lower urinary tract dysfunction.Dongxu ZhangFengze SunHuibao YaoXingjun BaoDi WangYuanshan CuiYuanshan CuiJitao WuFrontiers Media S.A.articlemeta-analysismirabegronneurogenic lower urinary tract dysfunctionRCTrandomized controlled trialsystematic reviewTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
meta-analysis mirabegron neurogenic lower urinary tract dysfunction RCT randomized controlled trial systematic review Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
meta-analysis mirabegron neurogenic lower urinary tract dysfunction RCT randomized controlled trial systematic review Therapeutics. Pharmacology RM1-950 Dongxu Zhang Fengze Sun Huibao Yao Xingjun Bao Di Wang Yuanshan Cui Yuanshan Cui Jitao Wu The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis |
| description |
Background and Objective: Over the past few years, mirabegron has been increasingly used as a therapeutic option for neurogenic lower urinary tract dysfunction. Here, we carried out a meta-analysis to investigate the efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction.Methods: We used a range of databases to retrieve randomized controlled trials (RCTs) relating to mirabegron in patients with neurogenic lower urinary tract dysfunction: PubMed, Embase, and Cochrane Library; our strategy conformed to the PICOS (populations, interventions, comparators, outcomes, and study designs) strategy.Results: Our analyses involved four RCTs involving 245 patients. We found that mirabegron treatment resulted in a significant improvement in bladder compliance [mean difference (MD) = 19.53, 95% confidence interval (CI): 14.19 to 24.87, P < 0.00001], urinary incontinence episodes (MD = −0.78, 95% CI: −0.89 to −0.67, P < 0.00001) and Incontinence Quality of Life (I-QOL) (MD = 8.02, 95% CI: 3.20 to 12.84, P = 0.001). Significant differences were detected in terms of Patient Perception of Bladder Condition (PPBC) (MD = −0.54, 95% CI: −1.46 to 0.39, P = 0.26) and urinary urgency episodes (MD = −0.72, 95% CI: −3.1 to 1.66, P = 0.55). With regard to safety, there were no significant differences between mirabegron and control groups in terms of the incidence of drug-related adverse events [odds ratio (OR): 0.83, 95% CI: 0.43 to 1.59, P = 0.57], arrhythmias (OR: 1.27, 95% CI: 0.37 to 4.38, P = 0.70), hypertension (OR: 0.70, 95% CI: 0.13 to 3.82, P = 0.68), or post-voiding residual volume (MD: 1.62, 95% CI: −9.00 to 12.24, P = 0.77).Conclusion: Mirabegron is an efficacious and safe treatment for patients with neurogenic lower urinary tract dysfunction. |
| format |
article |
| author |
Dongxu Zhang Fengze Sun Huibao Yao Xingjun Bao Di Wang Yuanshan Cui Yuanshan Cui Jitao Wu |
| author_facet |
Dongxu Zhang Fengze Sun Huibao Yao Xingjun Bao Di Wang Yuanshan Cui Yuanshan Cui Jitao Wu |
| author_sort |
Dongxu Zhang |
| title |
The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis |
| title_short |
The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis |
| title_full |
The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis |
| title_fullStr |
The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis |
| title_full_unstemmed |
The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis |
| title_sort |
efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction: a systematic review and meta-analysis |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/34666b1123054fabab7c18f7846f139b |
| work_keys_str_mv |
AT dongxuzhang theefficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT fengzesun theefficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT huibaoyao theefficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT xingjunbao theefficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT diwang theefficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT yuanshancui theefficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT yuanshancui theefficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT jitaowu theefficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT dongxuzhang efficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT fengzesun efficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT huibaoyao efficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT xingjunbao efficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT diwang efficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT yuanshancui efficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT yuanshancui efficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis AT jitaowu efficacyandsafetyofmirabegronforthetreatmentofneurogeniclowerurinarytractdysfunctionasystematicreviewandmetaanalysis |
| _version_ |
1718424527834185728 |